|
|
News Breaks | | | | January 30, 2013 | | 05:28 EDT |  | QGEN, GE | QIAGEN's KRAS companion diagnostic kit adopted by GE Healthcare's Clarient
QIAGEN (QGEN) announced that Clarient, a GE Healthcare (GE) company, has adopted the use of the therascreen KRAS RGQ PCR Kit as a companion diagnostic to guide the use of Erbitux as a treatment in patients with metastatic colorectal cancer. Clarient, with a customer base of more than 2,000 pathologists, oncologists, clinical laboratories and hospitals, selected QIAGEN's therascreen KRAS test and QIAGEN's Rotor-Gene Q MDx instrument following the FDA approval of the test in July 2012. Clarient joins a rapidly growing number of laboratories switching from laboratory-developed tests to the FDA-approved therascreen KRAS test for diagnostic testing for late stage colorectal cancer. | |
|
News For QGEN;GE From The Last 14 Days Check below for free stories on QGEN;GE the last two weeks. |
|
|
| There are no results for QGEN;GE |
|
|
|
|
|
|
